Litigation Details for ENCORE DERMATOLOGY INC. v. GLENMARK PHARMACEUTICALS LIMITED (D.N.J. 2020)
✉ Email this page to a colleague
ENCORE DERMATOLOGY INC. v. GLENMARK PHARMACEUTICALS LIMITED (D.N.J. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-03-05 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Kevin McNulty |
| Jury Demand | None | Referred To | |
| Patents | 9,956,231 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ENCORE DERMATOLOGY INC. v. GLENMARK PHARMACEUTICALS LIMITED
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for ENCORE DERMATOLOGY INC. v. GLENMARK PHARMACEUTICALS LIMITED (D.N.J. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-12-21 | 55 | Opinion | owns U.S. Patent No. 9,956,231 (the “Patent”), which expires in 2030. (Compl. ¶ 17.) The Patent claims “…in a patent or the use of which is claimed in a patent before the expiration of such patent. 35 … has a patent for a topical pharmaceutical composition with the compound clobetasol. The patent also provides…any patents relate to the proposed drug. Id. Relevant here, the applicant may assert that a patent “will… drug claimed in a patent or the use of which is claimed in a patent . . . if the purpose | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
